GoldBamboo.com - Knowledge is strong medicine
  

NIDDM and ACE2 - Article


  Not Signed In - Sign In / Register


Get Your Free Credit Report Right Now!

Zip Code:



General Topics A-Z

Candesartan

Atacand; candesartan cilexetil 



Clinical Trial: NIDDM and ACE2

This study is not yet open for patient recruitment.
Verified by Rambam Medical Center September 2005

Sponsored by: Rambam Medical Center
Information provided by: Rambam Medical Center
ClinicalTrials.gov Identifier: NCT00192803

Purpose

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with AT1R antagonist, Candesartan.

This study will provide a closer insight to the possible involvement of the RAS-related enzymatic components in development or attenuation of vascular pathogenesis.

Condition Intervention Phase
NIDDM patients
  Drug: candesartan
 Phase IV

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Educational/Counseling/Training, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Pharmacodynamics Study

Official Title: ACE/ACE2 Ratio in Diabetic Patients Treated with Antihypertensive Drugs

Further Study Details: 
Primary Outcomes: ACE and ACE2 activities in monocytes
Expected Total Enrollment:  20

Study start: November 2005

Eligibility

Ages Eligible for Study:  18 Years   -   90 Years,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • signed informed concent
  • non smokers
  • type II DM diagnosed patients
  • blood pressure < 135/90
  • serum HbA1C > 7%
  • serum creatinine < 1mg%
  • urine microalbumin < 300 mg/day
  • BMI < 35 kg/m2

Exclusion Criteria:

  • insulin-dependent diabetic patients
  • patient with persistent microalbuminuria
  • patient with history of sever hypertension
  • congestive heart failure
  • patient receiving RAAS-related anti-hypertensive medications.
  • patient with major hepatic disease

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00192803

Shlomo Keidar, MD      97248542518    skeidar@rambam.health.gov.il

Israel
      Internal Ward "A", Rambam Medical Center, Haifa,  Israel
Ayelet Raz, MD  972-4-8543072 
Ayelet Raz, MD,  Sub-Investigator

Study chairs or principal investigators

Shlomo Keidar, MD,  Principal Investigator,  Rambam Medical Center   

More Information

Study ID Numbers:  ACE2.CTIL
Last Updated:  September 16, 2005
Record first received:  September 14, 2005
ClinicalTrials.gov Identifier:  NCT00192803
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on 2005-09-20


Source: ClinicalTrials.gov
Cache Date: September 21, 2005

Resources



[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Candesartan.

November 23, 2009


Page Updated: September 6, 2005
============== Advertisement ==============
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Health Forums

Copyright © 2004-2009 - Anaconda Partners LLC - All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.